Teva Pharmaceutical Industries' (TEVA) US affiliate Teva Pharmaceuticals said Monday that an attitudes and experiences survey in connection with a schizophrenia trial showed patient and health care professional satisfaction with TEV-'749 or olanzapine as a once-monthly subcutaneous long-acting injectable.
The company said over 92% of patients, 87% of nurses and 72% of physicians were either satisfied or very satisfied when asked about the investigational treatment, which was evaluated in the phase 3 subcutaneous olanzapine extended-release injection study.
The company also said that new data from Uzedy assessed predictors of response in schizophrenia, with efficacy seen across patient demographic and clinical characteristics in the phase 3 trial.
Uzedy received approval in the US for the treatment of schizophrenia in adults in 2023, according to the company.
Shares of Teva Pharmaceutical Industries were up 2.6% in recent trading.
Price: 15.48, Change: +0.40, Percent Change: +2.63
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.